Diffuse large B-cell lymphoma accounts for up to 1/3 of the total NHL, which belongs to the solid tumor of B-cell generation, and the clinical manifestations of this disease are diverse. The incidence is greater in men than in women and develops rapidly. When lymphoma compresses and infiltrates various organs, it usually presents with high fever and symptoms of various organs, and the drug Porvy has a significant effect on the treatment of the disease.
Polivy indications
On June 10, 2019, the FDA accelerated the approval of Polvy (polatuzumab, bolotuzumab) in combination with the chemotherapy drugs bendamustine and rituximab products (called "BR") to treat adult DLBCL patients who had previously undergone at least two treatments but had worsened or relapsed.
Polivy mechanism of action: strangle dividing cells in the "cradle"!
Polivy is a CD79b-directed antibody-drug conjugate that can effectively inhibit the activity of B cells. The small molecule MMAE is an anti-mitosis agent that covalently attaches to an antibody through a cleavable joint. Monoclonal antibodies bind to CD79b, a B-cell-specific surface protein that is a component of b-cell receptors. When binding to CD79b, internalization is performed and the ligons are cleaved by lysosomal protease to enable intracellular delivery of MMAE. MMAE binds to microtubules to kill dividing cells by inhibiting cell division and inducing apoptosis.
Polivy Clinical Data: Safe and Effective, Providing a New Option for DLBCL Patients!
Polivy was randomly selected for 80 patients, with a median age of 69 years (range: 30-86 years), 66% male, and 71% white. The majority of patients (98%) had DLBCL without further indication. Of the 25 patients who achieved partial or complete remission, 16 (64%) had a DOR of at least 6 months and 12 (48%) had a DOR of at least 12 months. In the BR group, of the 10 patients who achieved partial or complete remission, 3 (30%) had DORs lasting at least 6 months and 2 (20%) had DORs lasting at least 12 months. The data proves that the drug is safe and effective, providing a new option for DLBCL patients!
Polivy Precautions: Know before taking!
1. The drug may cause peripheral neuropathy, please consult a doctor in time if there is an adverse reaction.
2. If there is bleeding or infection, please check the blood count regularly.
3. If nausea and vomiting occur, please seek medical attention immediately.
4. Potential risk to the fetus with reproductive potential or fetus.